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Over	 the	past	decade,	 there	has	been	an	explosion	of	 interest	 in	 the	 study	of	urinary	
and	plasma	biomarkers	for	the	rapid	diagnosis,	molecular	phenotyping	and	prognostication	of	
acute	 kidney	 injury	 (AKI)	with	 over	 3300	publications	 devoted	 to	 this	 topic	 listed	 in	 PubMed	
during	 the	 past	 10	 years.	 	 More	 than	 15	 separate	 biomarkers	 plasma	 and	 urine	 have	 been	
identified	 and	 investigated	 to	 various	 levels,	 the	majority	 in	 the	 context	 of	 AKI	 complicating	
critical	 illness[1].	 	 	 However,	 opinion	 remains	 divided	 as	 to	 the	 clinical	 value	 of	 biomarker	
measurements	in	the	care	of	patients	at	risk	or	with	acute	kidney	injury	as	reflected	in	opposing	
opinion	pieces	in	this	issue	of	Intensive	Care	Medicine.		While	we	agree	that	AKI	biomarkers	are	
not	 ready	 for	 implementation	 in	 routine	 care,	we	 feel	 that	 progress	 is	 being	made	 and	 that	
ultimately	there	may	be	important	roles	for	these	tools	in	the	care	of	critically	ill	patients.		
The	ultimate	 goal	 of	 biomarkers	 should	be	 to	 improve	outcomes	of	 patients	with	AKI	
and	 thus	 far,	 this	 high	 benchmark	 has	 not	 been	 realized.	 Much	 of	 the	 early	 promise	 of	





cohorts	 with	 differing	 clinical	 settings	 (post-surgery,	 post-procedure,	 sepsis,	 emergency	
department)	and	different	 timing	of	biomarker	measurements.	 	However,	 in	 just	about	every	
study,	 the	 discrimination	 for	 AKI	 detection	 is	 modest	 with	 area	 under	 the	 curves	 (AUCs)	
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typically	 between	 0.7	 and	 0.8	 for	 most	 biomarkers[1].	 	 Notably	 in	 the	 circumstances	 where	
biomarkers	performed	best,	such	as	pediatric	cardiac	surgery[2],	and	in	animal	models[3],	the	
renal	 insult	 was	 precisely	 timed,	 the	 cause	 of	 AKI	 fairly-uniform	 and	 the	 clinical	 population	




of	 mixed	 causes	 with	 variable	 underlying	 pathology	 and	 clinical	 course.	 Furthermore,	 we	
currently	diagnose	the	most	common	underlying	pathology	of	AKI,	renal	tubular	 injury,	based	
on	changes	in	serum	creatinine,	a	glomerular-filtration	marker	that	may	be	highly	confounded	
by	the	effects	of	acute	critical	 illness	and	its	treatment.	 	Finally,	AKI	 is	a	dynamic	process	that	
will	be	modified	by	host	response	to	illness,	medical	interventions	and	complicating	conditions	
and	there	is	a	point	when	‘early	diagnosis’	turns	into	to	‘predicting	the	future’.	Thus,	asking	a	
biomarker	 to	 accurately	 predict	 an	 evolving	 clinical	 process	 against	 a	 highly	 confounded	
diagnostic	standard	may	be	an	impossible	task	as	currently	defined[4].		
Alternatively,	 the	 diverse	 field	 of	 AKI	 biomarkers	 could	 provide	 important	 potential	
insights	 into	 the	 pathophysiology	 and	 mechanisms	 of	 AKI,	 such	 as	 renal	 inflammatory	
responses,	 cellular	 responses	 to	 injury	 (such	 as	 cell	 cycle	 arrest)	 and	 tubular	 vs.	 glomerular	
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define	 it,	 particularly	 as	 we	 have	 no	 proven	 AKI-targeted	 interventions	 to	 offer	 apart	 from	
supportive	care.		However,	to	discount	the	value	of	biomarkers	in	the	care	of	patients	with	AKI	
would	be	a	mistake.	 	 For	 example,	 the	positive	predictive	 values	 for	 identification	of	AKI	 are	
poor	(10-30%),	but	importantly,	negative	predictive	values	are	good	(86-97%)[6].		Thus,	clinical	
value	may	 lie	 in	directing	of	 low-risk	patients	away	from	expensive	 interventions	(such	as	 ICU	
care),	 much	 in	 the	 way	 that	 d-dimer,	 troponin	 and	 BNP	 are	 best	 used	 to	 rule	 out	 venous	
thromboembolism,	myocardial	infarction	and	heart	failure,	respectively.		
It	 is	 critical	 to	 understand	 that	 changes	 in	 biomarker	 levels	 describe	 a	 real	 biological	
process	 and	 this	may	 allow	 clinicians	 to	 think	 about	AKI	 in	 very	 different	ways.	 	 The	days	 of	
equating	AKI	with	 acute	 tubular	 necrosis	may	be	 coming	 to	 a	 close	 and	 instead	we	may	use	
biomarkers	 to	 phenotype	 injuries	 and	 pathological	 processes	 with	 an	 eventual	 goal	 of	
developing	more	effective	therapies.	 	For	example,	IL-18	is	an	attractive	target	for	biomarker-
directed	 therapy	 of	 AKI,	 because	 this	 cytokine	 seems	 to	 play	 a	 prominent	 role	 in	 the	
inflammatory	 processes	 that	 exacerbate	 renal	 injury	 during	 the	 extension	 phase	 of	 AKI[7].	
Therapies	that	disrupt	the	IL-18–signaling	axis	itself	could	prove	efficacious,	because	work	done	
in	animal	models	of	AKI	has	consistently	shown	that	doing	so	attenuates	renal	injury[7].			
We	would	 also	 argue	 that	 it	 is	 time	 to	 develop	more	 global	 strategies	 in	 the	 care	 of	
patients	with	AKI.			These	strategies	include	thinking	about	several	meaningful	clinical	outcomes	
such	as	 survival,	 length	of	 stay	or	 long	 term	renal	 function,	 rather	 than	any	conventional	AKI	
criteria.	However,	such	an	approach	requires	the	correct	combination	of	the	biomarker,	setting	
and	intervention.		
The	 promise	 of	 biomarkers	 is	 perhaps	 shown	 in	 a	 recent	 single	 center	 study	 that	
described	the	use	of	a	urinary	TIMP2xIGFBP7[8]	to	target	a	bundle	of	AKI-preventative	care	to	
patients	after	cardiac	surgery,	with	evidence	of	reduced	incidence	of	AKI	in	biomarker	positive	
patients	 randomized	to	 the	 intervention,	but	without	signal	of	benefit	 in	 terms	of	use	of	RRT	
and	 long-term	renal	 function.	This	 last	 result	 is	encouraging	 in	 that	 it	demonstrates	potential	
benefit	 of	 a	biomarker	 to	 identify	 a	high-risk	 group	 for	 a	preventative	 intervention;	 however	






–	 and	on	 the	 other	 expecting	 far	 too	 little	 –	 neglecting	 unique	 insights	 into	 underlying	 renal	
pathology	 that	 could	 be	 targets	 for	 therapy?	 	 Our	 premise	 is	 that	 while	 biomarkers	 are	 not	
ready	 for	 primetime	 use	 and	 future	 studies	 are	 clearly	 required,	 some	 applications	 such	 as	
identification	 of	 low-risk	 patients	 for	 lower-intensity	 care	 can	 be	 easily	 tested	 for	 safety	 and	
cost-effectiveness.	Conversely,	 interventional	studies	of	biomarker	targeted	intervention	are	a	
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Figure	1.	The	Promise	of	Biomarkers	
	
The	course	of	AKI	begins	at	the	initial	injury	(point	1)	where	biomarkers	may	be	useful	in	early	
diagnosis,	determination	of	the	location	of	injury	and	possibly	in	molecular	phenotyping	which	
could	lead	to	specific	therapies.		As	AKI	evolves	(points	2	and	3),	biomarkers	may	be	useful	in	
prognostication	and	help	clinicians	determine	whether	there	is	ongoing	injury	with	a	risk	of	
worsening	kidney	function	or	if	there	are	signs	of	recovery.		Biomarkers	may	also	provide	
information	on	the	future	risk	of	chronic	kidney	disease	(CKD),	end-stage	renal	disease	(ESRD)	
or	mortality.	
	
